Overview

* Anika Therapeutics ( ANIK ) Q2 rev falls 8% yr/yr but beats analyst expectations, per LSEG data

* Regenerative Solutions rev up 41%, driven by Integrity Implant System

* Hyalofast trial misses primary endpoints; shows improvement in secondary measures

Outlook

* Company maintains 2025 revenue guidance for Commercial and OEM Channels

* Anika updates 2026-2027 guidance due to Hyalofast launch delay

* Company expects US OA Pain Management pricing decline in H2 2025

* Anika plans Hyalofast PMA module submission in H2 2025

Result Drivers

* REGENERATIVE SOLUTIONS - Revenue increased 41% driven by Integrity Implant System and strong Hyalofast growth

* INTEGRITY IMPLANT - Surpassed full year 2024 performance and is on pace to more than double in 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $28.22 $27 mln

Revenue mln (3

Analysts

)

Q2 Net -$3.97

Income mln

Q2 Gross $14.36

Profit mln

Q2 -$4.18

Income mln

from

Operatio

ns

Q2 -$3.97

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Anika Therapeutics Inc ( ANIK ) is $21.00, about 46.9% above its July 29 closing price of $11.16

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)